source
- Agios halts development of next‑generation sickle‑cell drug tebapivat after disappointing mid‑stage trialAgios Therapeutics announced it will discontinue development of tebapivat, a next‑generation therapy for sickle cell disease, after the drug failed to demonstrate sufficient efficacy in a Phase 2 t…
- Agios drops next-gen sickle cell drug after Phase 2 data show no advantage over Novo’s candidateAgios Pharmaceuticals said it is halting development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a mid‑stage trial failed to demonstrate a benefit ove…